Glenmark Pharma Files FY26 Business Responsibility & Sustainability Report

Glenmark Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Reporting (BRSR) for the Financial Year 2025-26, as per SEBI regulations. The report details the company's corporate identity, registered and corporate addresses, and contact information for queries. It outlines the company's business activities, primarily focused on pharmaceuticals, encompassing research & development, manufacturing, and sales of generics, specialty medications, and OTC treatments across various therapeutic areas. The reporting boundary is standalone unless otherwise stated. The company operates 8 plants and 19 offices nationally, and 3 plants and 48 offices internationally, serving 28 states and 8 union territories in India and over 80 countries globally. Exports contributed 57.99% of the total standalone turnover.